Synonyms: BOL-303259-X | NCX-116 | PF-3187207 | Vyzulta®
latanoprostene bunod is an approved drug (FDA (2017))
Compound class:
Synthetic organic
Comment: Latanoprostene bunod is a NO-donating analogue of the prostaglandin F2α agonist latanoprost (isopropyl ester) [3]. This compound benefits from the additive hypotensive actions of both the prostaglandin agonist and NO. Latanoprostene bunod is the first NO-donating prostaglandin analogue to be granted FDA marketing approval [2,4].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
In vitro, BOL-303259-X increases guanylyl cyclase activity (NO-mediated cGMP formation) in PC12 (rat) and HEK293 (human) cells [3]. It is active in a variety of preclinical animal models [3]. Bioactivity vs. soluble guanylyl cyclase has been mapped to guanylyl cyclase α1β1 (GC-1), but as enzyme isoform is not specified, activation of the GC-2 isoform cannot be discounted. The value ascribed for agonist activity at the prostanoid FP receptor is derived from the published affinity of the parent compound active metabolite, latanoprost (free acid form). |
Selectivity at GPCRs | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|